

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

06 FEB 16 PM 4:47

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Biotechnology Industry Organization			
2. Address <input type="checkbox"/> Check if different than previously reported 1225 Eye Street, N.W., Suite 400 Washington DC 20005-5958 USA			
3. Principal place of business (if different than line 2) City State/Zip or Country			
4a. Contact Name Mr. Tom DiLenge	b. Telephone number (202) 962-6671	c. E-mail tdilenge@bio.org	5. Senate ID # 6245-12
7. Client Name <input checked="" type="checkbox"/> Self Biotechnology Industry Organization			6. House ID # 32505000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31)
9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐ ⇨ Termination Date _____ 11. No Lobbying Activity**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>2,980,000</u> 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options: <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Revenue Code
--	--

Senate Password Signature Brent Del Monte Date 2/13/2006Printed Name and Title Brent Del Monte, Vice President for Federal Government Relations

0000081326



Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code ACC - Accounting (one per page)

16. Specific lobbying issues

Sarbanes-Oxley
sec. 404, internal auditing controls

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, US Dept. of Treasury, SEC, White House, IRS

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Morrie	Ruffin	
W. Charles	Lucas	
Libby	Solon	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Lauren	Choi	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature Document digitally signed on Page 1.

Date 2/13/2006

Printed Name and Title Brent Del Monte, Vice President for Federal Government Relations
Filing #3909431e-59a0-4764-8950-393e3491295a - Page 3 of 62

10000081327



Ref

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code AGR - Agriculture (one per page)

16. Specific lobbying issues

Proposed regulatory policy regarding Adventitious Presence
Proposed regulatory policy regarding transgenic animals
HR 1563, S 767 National Food and Agriculture Science Act of 2005

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, FDA, USDA, Dept. of State, USTR, EPA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sean Darragh	
Michael Phillips	
Val Giddings	
Barbara Glenn	
Jim Eichhorst	
Dave Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Brent Erickson	
Matthew Carr	
Brent Del Monte	Counsel, House Energy and Commerce Committee

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



1381

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area AGR

16. Specific lobbying issues (continued from previous page)

HR 2744 Agriculture appropriations
funding for USDA/APHIS and FDA
FDA conflict of interest amendment
funding for Biomass R&D program

Biosafety Protocol

0000081329

POD

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

HR 2744 Agriculture; HR 2361 Interior; HR 2862 Commerce, Justice, State; HR 2360 Homeland Security (Appropriations Bills)
funding for USDA/APHIS and FDA
funding for Biomass R&D program and biorefinery commercialization programs
funding for NIH
funding for PTO

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, FDA, HHS, OMB, OSTP, USDA, EPA, Dept. of Energy, Dept. of Commerce, PTO, White House, Dept. of Justice

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Libby	Solon	
Val	Giddings	
Michael	Phillips	
Brent	Erickson	
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Lila	Feisee	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Matthew	Carr	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

0000081330

BSJ

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area BUD

16. Specific lobbying issues (continued from previous page)

HR 2744 Agriculture; HR 2361 Interior; HR 2862 Commerce, Justice, State; HR 2360 Homeland Security (Appropriations Bills) (cont.)

FDA conflict of interest amendment
reimportation
patent related amendment
funding for biodefense
controlled substances amendment
animal purchasing for biomedical research

Supplemental Appropriations
pandemic flu

HR 3010 Labor HHS Appropriations
funding for stem cell research
funding for NIH
funding for BioDefense

HR 2791 PTO Fee Bill

S 1932, HR 4241 Deficit Reduction Act of 2005 (Reconciliation)
Medicare and Medicaid payments savings

HR 2863 Defense Appropriations
funding for pandemic flu preparedness measures
liability limitations and compensation fund for pandemic and biodefense preparedness

1000081331

1387

Client Name Biotechnology Industry Organization

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

[illegible]

0000081712



RD

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

HR 2791 PTO Fee bill

HR 2862 Commerce, State, Justice Appropriations
funding for PTO
patent related amendment

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, PTO, NIH, Commerce Office of Science Policy, Dept. of State, HHS, USTR

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Lila	Feisee	
W. Charles	Lucas	
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Handwritten initials or signature.

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area CPT

16. Specific lobbying issues (continued from previous page)

HR 5299 Patent Quality Assistance Act of 2004

Human Cloning Patent Amendment

HR 2795 Patent Reform Act of 2005

apportionment of damages

first-to-file

evidentiary standard

injunctions (sec. 283)

continuation

Patent law harmonization

0000081334



107

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code DEF - Defense (one per page)

16. Specific lobbying issues

S 3 Protecting America in the War on Terror Act of 2005
funding, liability, contracting reform regarding biodefense

S 975 Project Bioshield II Act of 2005
R&D, regulatory issues, and contracting reform regarding biodefense

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, Dept. of Defense, White House, DOJ, HHS, FDA, NIH

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Brent	Erickson	
Sean	Darragh	
Val	Giddings	
W. Charles	Lucas	
Amit	Sachdev	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Chris	Colwell	
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



PS

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area DEF

16. Specific lobbying issues (continued from previous page)

HR 2863 Defense Appropriations
funding for pandemic flu preparedness measures
liability limitations and compensation fund for pandemic and biodefense preparedness

Biobased purchasing policy
biobased purchasing program and federal contractors

S 969 Attacking Viral Influenza Across Nations Act of 2005
funding, liability limitation

S 1437 Bioterrorism and Pandemic Preparedness Act of 2005
funding, liability limitation, procurement reform

S. 1873 Biodefense and Pandemic Vaccine and Drug Development Act of 2005
liability limitation, regulatory support, procurement reform, agriculture-related provisions

HR 3970 Bioterror and Pandemic Preparedness Protection Act
liability limitation

0000081336

POSD

Client Name Biotechnology Industry Organization

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

[illegible]

Add a page to continue adding lobbyists for this

7
N
I
8
0
0
0
0



B87D

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code ENG - Energy/Nuclear (one per page)

16. Specific lobbying issues

HR 6, S 10 Energy Policy Act of 2005
biomass R&D program, biorefinery commercialization, bioproducts procurement programs
HR 1608, S 650 Fuels Security Act
biomass R&D program, biorefinery commercialization, bioproducts procurement programs
S 1210 National Security & Bioenergy Investment Act of 2005
biomass R&D program, biorefinery commercialization, bioproducts procurement programs

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, Dept. of Commerce, Dept. of Energy, Dept. of Defense, Dept. of Agriculture, White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Brent Erickson	
Matthew Carr	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

12/30

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area ENG

16. Specific lobbying issues (continued from previous page)

Bioenergy legislation

Funding for R&D of advanced biotech and energy and chemical production

Agriculture policy

Biobased purchasing policy

biobased purchasing program and federal contractors

1000081339

1800

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code FOO - Food Industry (Safety, Labeling, etc.) (one per page)

16. Specific lobbying issues

HR 753, S 184 Safe IMPORT Act

HR 1563, S 767 National Food and Agricultural Science Act of 2005

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, EPA, USDA, FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Val Giddings	
Michael Phillips	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HOM - Homeland Security (one per page)

16. Specific lobbying issues

S 3 Protecting America in the War on Terror Act of 2005
funding, liability, contracting reform regarding biodefense

S 975 Project Bioshield II Act of 2005
R&D, regulatory issues, and contracting reform regarding biodefense

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, Dept. of Defense, White House, DOJ, HHS, FDA, NIH

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Brent	Erickson	
Sean	Darragh	
Val	Giddings	
W. Charles	Lucas	
Amit	Sachdev	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Chris	Colwell	
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Red

Biotechnology Industry Organization
Registrant Name _____ Client Name _____
Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area HOM

16. Specific lobbying issues (continued from previous page)

HR 2863 Defense Appropriations
funding for pandemic flu preparedness measures
liability limitations and compensation fund for pandemic and biodefense preparedness

Biobased purchasing policy
biobased purchasing program and federal contractors

S 969 Attacking Viral Influenza Across Nations Act of 2005
funding, liability limitation

S 1437 Bioterrorism and Pandemic Preparedness Act of 2005
funding, liability limitation, procurement reform

S. 1873 Biodefense and Pandemic Vaccine and Drug Development Act of 2005
liability limitation, regulatory support, procurement reform, agriculture-related provisions

HR 3970 Bioterror and Pandemic Preparedness Protection Act
liability limitation

0000081342



1 BGD

Client Name Biotechnology Industry Organization

Add a page to continue adding lobbyists for this



POD

11
12
13

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

HR 810, S 471 Stem Cell Research Enhancement Act of 2004
HR 1650 Stem Cell Research Investment Act
HR 596, S 681 Cord Blood Stem Cell Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, HHS, NIH, FDA, Dept. of State, CDC, NIST, White House

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Amit	Sachdev	
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Sara	Radcliffe	
W. Charles	Lucas	
Lila	Feisee	
Libby	Solon	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Andrew	Emmett	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

0000081344



Biotechnology Industry Organization
 Registrant Name _____ Client Name _____

ADDENDUM for General Lobbying Issue Area MED

16. Specific lobbying issues (continued from previous page)

HR 2520 Stem Cell Therapeutic & Research Act

HR 182, S 876 Human Cloning Ban & Stem Cell Research Protection Act

S 317 Bone Marrow & Cord Blood Therapy & Research Act

HR 1227, S 306 Genetic Information Nondiscrimination Act of 2005

HR 3010 Labor HHS Appropriations Bill
 funding for stem cell research
 funding for NIH
 funding for BioDefense

Clinical trial information disclosure

Bayh-Dole March-in rights

NIH Conflict of Interest

FDA review practices

FDA drug safety
 conflict of interest provisions
 PDUFA
 Grassley drug safety bill

Cell, gene, and tissue therapy

Pharmacogoneomics
 personalized medicine

PDUFA implementation
 FDA finances, information technology

HR 2744 Agriculture Appropriations
 animal purchasing for biomedical research

/

0000081345



PSD



Handwritten signature or initials.

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Medicare Modernization Act Implementation
Part D (prescription drug benefit)
S 1932, HR 4241 Deficit Reduction Act of 2005 (Reconciliation)
Medicare and Medicaid payments savings
Off-Label studies

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, HHS, CMS, OMB, White House

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Alan	Eisenberg	Policy Advisor, Rep. James Greenwood
Amit	Sachdev	
Jayson	Slotnik	
Libby	Solon	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
W. Charles	Lucas	
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



BD

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area MMM

16. Specific lobbying issues (continued from previous page)

0000081548



Red

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

FDA Issues
post-market surveillance, clinical trials, drug reviews
drug manufacturing, counterfeiting, PDUFA, reimportation, conflict of interest

D.C. Prescription Drug Excessive Pricing Act of 2005

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, HHS, FDA, OMB, White House, CMS

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
W. Charles	Lucas	
Amit	Sachdev	
Libby	Solon	
Sara	Radcliffe	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Andrew	Emmett	
Jayson	Slotnik	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



POD

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area PHA

16. Specific lobbying issues (continued from previous page)

S 1932, HR 4241 Deficit Reduction Act of 2005 (Reconciliation)
Medicare and Medicaid payments savings

30000081350



Boo

|

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code SCI - Science/Technology (one per page)

16. Specific lobbying issues

HR 2943, S 1263 Save America's Biotechnology Innovative Research Act
HR 250 Manufacturing Technology Competitiveness Act of 2005
HR 6, S 10 Energy Policy Act of 2005
funding for Biomass R&D program

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, SBA, White House, NIH

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Libby	Solon	
Morrie	Ruffin	
Brent	Erickson	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Lauren	Choi	
Grant	Erdel	Admin. Assistant to Rep. JoAnn Emerson

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Bo

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code SMB - Small Business (one per page)

16. Specific lobbying issues

HR 2942, S 1263 Save America's Biotechnology Innovative Research Act

IRC Sec. 382
taxes on net operating losses

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, SBA, White House, NIH

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Lauren	Choi	
Morrie	Ruffin	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Libby	Solon	
Susie	Ahn	Senior Legislative Assistant for Rep. Mike Honda
Grant	Erdel	Admin. Assistant to Rep. JoAnn Emerson

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

1

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code TAX - Taxation/Internal Revenue Code (one per page)

16. Specific lobbying issues

HR 1736, S 627 Investment in America Act (R&D) tax credit

Stock options 49(a) regulatory scheme

IRC Sec. 382
taxes on net operating losses

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, Dept. of Treasury, SEC, White House, IRS

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Morrie	Ruffin	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Libby	Solon	
Lauren	Choi	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

HR 2045 CAFTA Implementation Bill

WTO Case on Moratorium in EU on Genetically Modified Foods

WTO Case on Traceability and Labeling

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives, US Senate, White House, EPA, Dept. of State, USDA, FDA, PTO, USTR

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Brent	Del Monte	Counsel, House Energy and Commerce Committee
Val	Giddings	
Michael	Phillips	
Brent	Erickson	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Lila	Feisee	
Libby	Solon	/
Sean	Darragh	
W. Charles	Lucas	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

0000081354



840

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area TRD

16. Specific lobbying issues (continued from previous page)

Trade Related IP Agreements
TRIPS & the inclusion of disclosure requirements for the Convention on Biological Diversity, bioprospecting appropriation

Patent Law Harmonization

1000081355

[Handwritten signature]

Client Name Biotechnology Industry Organization

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

[illegible]

Add a page to continue adding lobbyists for this

CONFIDENTIAL



Red